Showing 1711 results
-
Press release /Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved…
-
Press release /V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%…
-
Featured News /We’re honoring World Cancer Day with a new series called “Let’s Talk About the C Word: From Cancer to Cures” to address challenging conversations on cancer.
-
Featured News /
Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.
-
Press release /Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening…
-
Press release /- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
-
Press release /83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63…